NASDAQ:APLS - Apellis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $128.43
  • Forecasted Upside: 108.39 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 11 Buy Ratings
  • 1 Strong Buy Ratings
$61.63
▲ +1.52 (2.53%)

This chart shows the closing price for APLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Apellis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APLS

Analyst Price Target is $128.43
▲ +108.39% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $128.43, with a high forecast of $875.00 and a low forecast of $39.00. The average price target represents a 108.39% upside from the last price of $61.63.

This chart shows the closing price for APLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 polled investment analysts is to buy stock in Apellis Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/28/2020
  • 1 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/26/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/24/2020
  • 1 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/23/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/23/2021
  • 1 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/22/2021
  • 1 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 1 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2021UBS GroupInitiated CoverageBuy$82.00Low
5/18/2021BMO Capital MarketsBoost Price TargetOutperform$64.00 ➝ $68.00High
5/18/2021OppenheimerBoost Price TargetOutperform ➝ Outperform$64.00 ➝ $67.00Medium
5/17/2021Raymond JamesBoost Price TargetStrong-Buy$104.00 ➝ $115.00Medium
5/17/2021Roth CapitalBoost Price TargetBuy$69.00 ➝ $80.00High
4/29/2021Credit Suisse GroupBoost Price TargetNeutral$37.00 ➝ $39.00High
4/16/2021The Goldman Sachs GroupInitiated CoverageBuy$130.00Medium
2/26/2021Credit Suisse GroupBoost Price TargetNeutral$35.00 ➝ $37.00High
1/29/2021Credit Suisse GroupBoost Price TargetNeutral$31.00 ➝ $35.00High
1/8/2021Raymond JamesBoost Price TargetStrong-Buy$78.00 ➝ $104.00Low
12/15/2020Roth CapitalBoost Price TargetBuy$50.00 ➝ $73.00Low
12/10/2020CowenBoost Price TargetOutperform$45.00 ➝ $55.00Medium
12/4/2020JPMorgan Chase & Co.Boost Price Target$50.00 ➝ $875.00Medium
12/1/2020BMO Capital MarketsBoost Price TargetOutperform$57.00 ➝ $66.00Low
11/23/2020Smith Barney CitigroupBoost Price Target$53.00 ➝ $67.00Low
11/23/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price TargetBuy$53.00 ➝ $67.00High
11/19/2020Needham & Company LLCInitiated CoverageBuy$59.00Low
10/9/2020Cantor FitzgeraldReiterated RatingOverweightLow
8/31/2020Stifel NicolausInitiated CoverageBuy$40.00High
7/20/2020Roth CapitalInitiated CoverageBuy$50.00High
6/30/2020CitigroupLower Price TargetBuy$56.00 ➝ $54.00High
6/16/2020BTIG ResearchInitiated CoverageNeutralHigh
6/12/2020OppenheimerReiterated RatingBuy$62.00High
6/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$54.00 ➝ $56.00High
5/28/2020UBS GroupInitiated CoverageAddMedium
4/28/2020Cantor FitzgeraldBoost Price TargetOverweight$54.00 ➝ $61.00High
3/31/2020Raymond JamesInitiated CoverageStrong-Buy$86.00High
3/31/2020BMO Capital MarketsInitiated CoverageOutperform$54.00High
3/11/2020WedbushUpgradeUnderperform ➝ Neutral$29.00High
3/2/2020Credit Suisse GroupLower Price TargetNeutral$36.00 ➝ $34.00High
2/28/2020CowenReiterated RatingBuy$40.00High
1/7/2020Cantor FitzgeraldReiterated RatingBuy$54.00High
1/7/2020OppenheimerBoost Price TargetBuy$52.00 ➝ $62.00High
1/7/2020CitigroupBoost Price Target$37.00 ➝ $80.00High
1/7/2020CowenReiterated RatingBuy$40.00High
1/7/2020SVB LeerinkInitiated CoverageMarket Perform$30.00High
1/7/2020Robert W. BairdReiterated RatingOutperform ➝ Overweight$45.00 ➝ $70.00High
12/19/2019Bank of AmericaInitiated CoverageBuy$36.00High
11/27/2019WedbushInitiated CoverageUnderperform$23.00N/A
11/25/2019Cantor FitzgeraldReiterated RatingOverweight$50.00 ➝ $54.00Medium
11/21/2019WedbushInitiated CoverageUnderperform$23.00High
11/5/2019Credit Suisse GroupInitiated CoverageNeutral$33.00Medium
10/17/2019Cantor FitzgeraldReiterated RatingOverweightLow
8/1/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$52.00 ➝ $50.00Low
7/31/2019CowenSet Price TargetBuy$40.00Medium
7/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$35.00 ➝ $49.00High
7/9/2019OppenheimerInitiated CoverageOutperform$52.00 ➝ $52.00High
6/16/2019CowenReiterated RatingBuy$40.00High
5/8/2019Cantor FitzgeraldReiterated RatingBuy$52.00Medium
3/28/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$45.00Low
2/28/2019Cantor FitzgeraldSet Price TargetBuy$57.00High
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$34.00High
1/8/2019B. RileyInitiated CoverageBuy$40.00Low
12/20/2018Cantor FitzgeraldReiterated RatingBuy$53.00High
12/6/2018CitigroupBoost Price TargetBuy$34.00 ➝ $40.00Medium
12/3/2018Cantor FitzgeraldSet Price TargetBuy$53.00High
11/14/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$38.00 ➝ $34.00High
11/12/2018Cantor FitzgeraldSet Price TargetBuy$53.00Low
10/1/2018Cantor FitzgeraldSet Price TargetBuy$53.00Low
9/13/2018B. RileyBoost Price TargetBuy$27.00 ➝ $40.00Low
9/4/2018Cantor FitzgeraldSet Price TargetBuy$53.00High
8/7/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Buy$52.00 ➝ $53.00Medium
8/1/2018CowenReiterated RatingBuy$40.00Medium
7/31/2018Cantor FitzgeraldSet Price TargetBuy$52.00High
7/30/2018B. RileyUpgradeNeutral ➝ Buy$27.00High
7/10/2018CowenInitiated CoverageOutperform$40.00Low
6/27/2018Cantor FitzgeraldReiterated RatingBuy$52.00High
6/7/2018Cantor FitzgeraldSet Price TargetBuy$52.00Low
5/23/2018Cantor FitzgeraldInitiated CoverageOverweightLow
4/12/2018B. RileyDowngradeBuy ➝ Neutral$27.00High
3/23/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$31.00 ➝ $35.00Low
2/8/2018B. RileyInitiated CoverageBuy ➝ Buy$27.00Low
12/4/2017Evercore ISIInitiated CoverageOutperformHigh
12/4/2017CitigroupInitiated CoverageBuy$23.00High
12/4/2017JPMorgan Chase & Co.Initiated CoverageOverweight$31.00High
(Data available from 6/22/2016 forward)
Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $61.63
Low: $59.46
High: $61.96

50 Day Range

MA: $51.34
Low: $42.24
High: $64.90

52 Week Range

Now: $61.63
Low: $25.49
High: $65.67

Volume

361,794 shs

Average Volume

716,685 shs

Market Capitalization

$4.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Apellis Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Apellis Pharmaceuticals in the last year: BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Credit Suisse Group AG, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Roth Capital, Smith Barney Citigroup, Stifel Nicolaus, The Goldman Sachs Group, Inc., UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for APLS.

What is the current price target for Apellis Pharmaceuticals?

14 Wall Street analysts have set twelve-month price targets for Apellis Pharmaceuticals in the last year. Their average twelve-month price target is $128.43, suggesting a possible upside of 108.4%. JPMorgan Chase & Co. has the highest price target set, predicting APLS will reach $875.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $39.00 for Apellis Pharmaceuticals in the next year.
View the latest price targets for APLS.

What is the current consensus analyst rating for Apellis Pharmaceuticals?

Apellis Pharmaceuticals currently has 1 hold rating, 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APLS will outperform the market and that investors should add to their positions of Apellis Pharmaceuticals.
View the latest ratings for APLS.

What other companies compete with Apellis Pharmaceuticals?

How do I contact Apellis Pharmaceuticals' investor relations team?

Apellis Pharmaceuticals' physical mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company's listed phone number is 617-977-5700 and its investor relations email address is [email protected] The official website for Apellis Pharmaceuticals is www.apellis.com.